Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 20/20 | 0.61 |
| ▸ | PDGFRB | P09619 | 14/20 | 0.61 |
| ▸ | PDGFRA | P16234 | 14/20 | 0.61 |
| ▸ | SRC | P12931 | 12/20 | 0.61 |
| ▸ | FGFR2 | P21802 | 6/20 | 0.61 |
| ▸ | FGFR4 | P22455 | 6/20 | 0.61 |
| ▸ | FGFR3 | P22607 | 6/20 | 0.61 |
| ▸ | EGFR | P00533 | 4/20 | 0.61 |
| ▸ | FLT1 | P17948 | 1/20 | 0.48 |
| ▸ | FLT4 | P35916 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.45 |
| ▸ | PRKCG | P05129 | 1/20 | 0.45 |
| ▸ | PRKCB | P05771 | 1/20 | 0.45 |
| ▸ | PRKCA | P17252 | 1/20 | 0.45 |
| ▸ | PRKCH | P24723 | 1/20 | 0.45 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | PRKCI | P41743 | 1/20 | 0.45 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2348899 | 0.88 | FGFR1 (0.62) | FGFR1PDGFRBPDGFRASRCFGFR2 | |
| SCHEMBL2355675 | 0.88 | FGFR1 (0.63) | FGFR1PDGFRBPDGFRASRCFGFR2 | |
| SCHEMBL2351653 | 0.87 | FGFR1 (0.63) | FGFR1PDGFRBPDGFRASRCFGFR2 | |
| SCHEMBL465419 | 0.87 | FGFR1 (0.64) | FGFR1PDGFRBPDGFRASRCFGFR2 | |
| SCHEMBL2349401 | 0.87 | FGFR1 (0.63) | FGFR1PDGFRBPDGFRASRCFGFR2 | |
| SCHEMBL4873535 | 0.86 | FGFR1 (0.58) | FGFR1PDGFRBPDGFRASRCFGFR2 | |
| SCHEMBL2350863 | 0.84 | FGFR1 (0.65) | FGFR1PDGFRBPDGFRASRCFGFR2 | |
| SCHEMBL12863157 | 0.79 | FGFR1 (0.59) | FGFR1PDGFRBPDGFRASRCFGFR2 | |
| SCHEMBL2352385 | 0.79 | FGFR1 (0.57) | FGFR1PDGFRBPDGFRASRCFGFR2 | |
| SCHEMBL8130610 | 0.76 | FGFR1 (1.00) | FGFR1PDGFRBPDGFRASRCFGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163522-A1 | Derivatives of Pyrido[2,3-d]pyrimidine, the Preparation Thereof, and the Therapeutic Application of the Same | SANOFI-AVENTIS (FR) | 2009-06-25 | — | — | US | claimed |
| US-7504406-B2 | Derivatives of pyrido[2,3-d]pyrimidine, the preparation thereof, and the therapeutic application of the same | SANOFI-AVENTIS (FR) | 2009-03-17 | — | — | US | claimed |
| US-20080176874-A1 | Derivatives of Pyrido[2,3-d]pyrimidine, the Preparation Thereof, and the Therapeutic Application of the Same | SANOFI-AVENTIS (FR) | 2008-07-24 | — | — | US | claimed |
| US-8008310-B2 | Derivatives of pyrido[2,3-d]pyrimidine, the preparation thereof, and the therapeutic application of the same | SANOFI-AVENTIS (FR) | 2011-08-30 | — | — | US | disclosed |
| US-20090163522-A1 | Derivatives of Pyrido[2,3-d]pyrimidine, the Preparation Thereof, and the Therapeutic Application of the Same | SANOFI-AVENTIS (FR) | 2009-06-25 | — | — | US | disclosed |
| US-7504406-B2 | Derivatives of pyrido[2,3-d]pyrimidine, the preparation thereof, and the therapeutic application of the same | SANOFI-AVENTIS (FR) | 2009-03-17 | — | — | US | disclosed |
| EP-1902054-B1 | DERIVATIVES OF PYRIDO[2,3-D]PYRIMIDINE, THE PREPARATION THEREOF AND THE THERAPEUTIC APPLICATION OF THE SAME | SANOFI AVENTIS (FR) | 2009-02-18 | — | — | EP | disclosed |
| EP-2020410-A1 | Pyrido[2,3d]pyrimidine derivatives, process for their preparation and their therapeutical use | sanofi-aventis (FR) | 2009-02-04 | — | — | EP | disclosed |
| US-20080176874-A1 | Derivatives of Pyrido[2,3-d]pyrimidine, the Preparation Thereof, and the Therapeutic Application of the Same | SANOFI-AVENTIS (FR) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176874-A1 | Derivatives of Pyrido[2,3-d]pyrimidine, the Preparation Thereof, and the Therapeutic Application of the Same | DPYD, TYMP, TYMS | FGFR1 2373/4885PDGFRB 432/4885PDGFRA 672/4885 |
| US-20090163522-A1 | Derivatives of Pyrido[2,3-d]pyrimidine, the Preparation Thereof, and the Therapeutic Application of the Same | DPYD, TYMP, TYMS | FGFR1 2373/4885PDGFRB 432/4885PDGFRA 672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.